CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
Go back to CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology| (NASDAQ: CGON) | Delayed: 73.77 -0.9 (1.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $74.67 | 52 Week High | $ | |||
| Open | $73.23 | 52 Week Low | $ | |||
| Day High | $74.60 | P/E | N/A | |||
| Day Low | $72.25 | EPS | $ | |||
| Volume | 39,247 | |||||
